NCT05392764招募中3 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Empagliflozin in Patients With Acute Heart Failure
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 444
- 试验地点
- 69
- 主要终点
- A hierarchical composite endpoint consisting of death within 90 days, heart failure rehospitalization within 90 days, WHF during hospitalization, and urine output up to 48 hours after treatment initiation, assessed by the win ratio
研究概览
简要总结
The EMPA-AHF trial is a multicentre, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of early initiation of once-daily oral empagliflozin 10 mg in patients hospitalized for patients with acute heart failure (AHF) who are at a high risk of adverse events.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 89 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who meet the below inclusion criteria will be randomized within 12 h after presentation to the hospital
- •Age of ≥20*
- •Hospitalized with a diagnosis of acute heart failure, requiring intravenous loop diuretic therapy, and with all of the following characteristics:
- •i. Dyspnoea at rest or induced by slight exertion ii. At least two of the following findings: jugular venous distention, pulmonary rales, lower leg edema, and pulmonary congestion on chest X-ray iii. If the patient has a sinus rhythm at the time of admission, BNP ≥350 pg/mL or NT-proBNP ≥1400 pg/mL; if the patient has atrial fibrillation at the time of admission, BNP ≥500 pg/mL or NT-proBNP ≥2000 pg/mL. For patients taking an angiotensin receptor neprilysin inhibitor, only the reference value for NT-proBNP will be applicable.
- •At least one of the following characteristics:
- •i. eGFR <60 mL/min/1.73m2, as calculated using the CKD Epidemiology Collaboration for JapaneseModification of Diet in Renal Disease formula ii. Already taking ≥40 mg of oral furosemide during the period before hospitalization. For patients on loop diuretics other than furosemide, the following conversion should be used: oral furosemide 20 mg = oral azosemide 30 mg = oral torasemide 5 mg.
- •iii. Urine output of <300 mL during the 2 h following an appropriate dose of intravenous furosemide administered after hospitalization. An appropriate dose of intravenous furosemide is 20 mg for patients who have not been taking furosemide regularly before hospitalization and is the same as, or greater than, the daily oral dose for patients who have been taking furosemide regularly before hospitalization.
- •Provided written consent to participate in the study *If the patient is 90 years of age or older and cognitive decline is considered necessary, Mini-Cog should be used to confirm that its score is not less than 3.
排除标准
- •eGFR <20 mL/min/1.73m2 at the time of admission
- •Already taking an SGLT2i within 3 months prior to hospitalization
- •Type 1 diabetes mellitus
- •Systolic blood pressure <90 mmHg
- •Expected to newly require treatment with thiazide, tolvaptan, or carperitide within 48 hours of study drug administration
- •Main cause of acute heart failure hospitalization is not fluid retention (e.g., persistent ventricular tachycardia, persistent atrial fibrillation/atrial flutter with a ventricular response rate of ≥130 bpm, persistent bradycardia with a ventricular response rate of <45 bpm, an infection, severe anemia, and an acute exacerbation of COPD)
- •Acute coronary syndrome, pulmonary thromboembolism, or a cerebrovascular accident is the main cause of the present hospitalization.
- •At risk of ketoacidosis or hyperosmolar hyperglycaemia
- •On dialysis, including peritoneal dialysis, or the initiation of dialysis during hospitalization is planned
- •Pregnant or lactating women
- •Underwent the following therapeutic interventions within 30 days: cardiovascular surgery (e.g., coronary artery bypass grafting, surgery for valvular heart disease, transcatheter aortic valve implantation, percutaneous coronary intervention, percutaneous edge-to-edge mitral valve repair, and other types of surgery at the investigator's discretion) and implantation of an implantable defibrillator, cardiac resynchronization therapy defibrillator, or implantable ventricular-assist device
- •A diagnosis of acute coronary syndrome, cerebral infarction, or transient ischemic attack made within 90 days
- •Ventricular tachycardia with syncope within 90 days
- •Heart transplant recipient or listed for heart transplantation and expected to undergo transplantation during the present treatment; implanted with an implantable ventricular-assist device or expected to require an implantable ventricular-assist device during the present treatment; or expected to switch to palliative care
- •Intubated at the time of screening or expected to require intubation within within 48 hours of study drug administration
- •Severe valvular heart disease expected to be treated with thoracostomy or catheterization (a reason to exclude secondary mitral or tricuspid regurgitation due to reduced cardiac function does not exist, except for the absence of a plan to perform cardiac surgery or therapeutic catheterization)
- •A diagnosis of secondary cardiomyopathy such as amyloidosis, cardiac sarcoidosis, hemochromatosis, Fabry disease, and muscular dystrophy. Heart failure due to takotsubo cardiomyopathy, obstructive hypertrophic cardiomyopathy, complex congenital heart disease (as determined by the investigator), or pericardial constriction.
- •A diagnosis of peripartum cardiomyopathy made within 6 months
- •Active myocarditis
- •Presence of uncontrolled thyroid disease
- •Acute cardiac structural abnormalities (e.g., acute mitral regurgitation due to ruptured chordae tendineae)
- •Symptomatic bradycardia or complete atrioventricular block, being treated with a temporary pacemaker implantation at the time of admission, or expected to require a temporary pacemaker implantation in the future. Patients who have already been treated with a permanent pacemaker implantation do not meet the exclusion criteria.
- •Serious liver disorder (an increase in AST, ALT, or ALP level ≥3 times the upper limit of normal) or cirrhosis with varices or other findings suggestive of portal hypertension
- •Alcohol use disorder of at least mild severity according to the DSM-V
- •A diagnosis of active malignancy or suspected active malignancy made within 2 years
- •Coexisting diseases other than heart failure with an expected survival prognosis of ≤1 year
- •Participation in a clinical study of another drug 30 days before hospitalization
- •Patients considered to require fasting at screening.
- •Other conditions likely to interfere with the patient's safety or compliance with the protocol
- •Other patients who are considered unsuitable by the principal investigator or other investigators
研究组 & 干预措施
Placebo
Placebo Comparator
Placebo matching empagliflozin
干预措施: Placebo (Drug)
Empagliflozin
Experimental
Patients will be randomized 1:1 to either empagliflozin or placebo.
干预措施: Empagliflozin 10 MG (Drug)
结局指标
主要结局
A hierarchical composite endpoint consisting of death within 90 days, heart failure rehospitalization within 90 days, WHF during hospitalization, and urine output up to 48 hours after treatment initiation, assessed by the win ratio
时间窗: Up to 90 days
WHF, worsening heart failure
次要结局
- A hierarchical composite endpoint consisting of death within 90 days, heart failure readmission within 90 days, and WHF during hospitalization(Up to 90 days)
- A composite endpoint consisting of WHF during hospitalization, death, heart failure rehospitalization, urgent visit for WHF, intensification of diuretic therapy, and worsening NYHA class within 90 days(Up to 90 days)
- Change in NT-proBNP from randomization to 48 hours(Evaluated at 48 hours after randomization)
- Diuretic response, calculated as urine output achieved by loop diuretics (40 mg intravenous furosemide-equivalent dose) at 48 h after treatment initiation(Evaluated at 48 hours after randomization)
- Time to hemodynamic stabilization during index hospitalization(During index hospitalization)
- Urine output during the 48 h after randomization(Evaluated at 48 hours after randomization)
- Cardiovascular death(Up to 90 days)
- Change in the visual analog scale score for dyspnea from after randomization to 24 and 48 h(Evaluated at 24 and 48 hours after randomization)
- Composite of renal replacement therapy, renal transplantation, eGFR <15 mL/min/1.73m2, ≥50% decrease in eGFR compared to the first sample or a ≥2-fold increase in creatinine level compared to the first sample within 90 days of randomization(Up to 90 days)
- Improvement in KCCQ-TSS of ≥5 points from randomization to 30 and 90 days after treatment initiation(Up to 90 days)
- Trend in eGFR after randomization to 24 h, 48 h, 30 days, and 90 days(Up to 90 days)
- Re-worsening of heart failure during index hospitalization(During index hospitalization)
- Death(Up to 90 days)
- Change in the KCCQ-TSS after randomization to 30 and 90 days(Up to 90 days)
- Heart failure rehospitalization(Up to 90 days)
- Change in high sensitivity cardiac troponin T(Evaluated at 48 hours after randomization)
- Days alive and out of hospital (including those for reasons other than heart failure)(Up to 90 days)
研究者
Yuya Matsue
Associate Professor
Juntendo University
研究点 (69)
Loading locations...
相似试验
已完成
3 期
Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19Mild to Moderate COVID-19NCT05620160Guangdong Raynovent Biotech Co., Ltd1,359
已完成
2 期
Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19COVID-19 PneumoniaNCT05656443Fujian Akeylink Biotechnology Co., Ltd.1,246
已完成
2 期
A Study of MHAA4549A in Healthy Volunteers in an Influenza Challenge ModelHealthy VolunteerNCT01980966Genentech, Inc.101
已完成
2 期
Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASHNON-ALCOHOLIC STEATOHEPATITISNCT06054815NeuroBo Pharmaceuticals Inc.109
Unknown
3 期
A Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A in Patients With Overactive Bladder (OAB)Overactive BladderNCT02786407Lanzhou Institute of Biological Products Co., Ltd216